Interestingly, a prognosis for breast cancer is better during the first 7 years for patients with a high SLC22A5 expression level; after this period, it is the other way round and a prognosis is much better in case of patients with a low expression level (Figure 4A). This evidence concerns the gene SLC22A5 and breast cancer.